IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: AdreView is contraindicated in patients with known hypersensitivity to iobenguane or iobenguane sulfate.


See Indications and Important Safety Information about AdreView at the bottom of this page.

Please also read the Full Prescribing Information.

AdreView is the only FDA-approved I-123-meta-iodobenzylguanidine (I-123-mIBG) imaging agent indicated for use in the detection of primary or metastatic pheochromocytoma or neuroblastoma, as an adjunct to other diagnostic tests1

• Key benefits of AdreView include:

    – High sensitivity and specificity demonstrated in pivotal clinical trials in both newly diagnosed and previously treated neuroblastoma2 and pheochromocytoma3
    – As a GE Healthcare proprietary product, customers can count on outstanding product quality, consistency, and reliability

1. AdreView [prescribing information]. Arlington Heights, IL: GE Healthcare; 2013
2. Vik TA, Pfluger T, Kadota R, Castel V, et al. 123I-mIBG Scintigraphy in Patients With Known or Suspected Neuroblastoma: Results From a Prospective Multicenter Trial. Pediatr Blood Cancer. 2009; 52: 784-790
3. Wiseman GA, Pacak K, O’Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

Indications

  • Reimbursement

    See Important Safety Information about AdreView at the bottom of this page.

    Please also read the Full Prescribing Information.

    GE Healthcare Medical Diagnostics Reimbursement

    GE Healthcare advocates for timely patient access to medically appropriate, high quality imaging services, provided by knowledgeable and skilled providers of care. We recognize the significant impact that reimbursement policies can have on you and your practice and strive to provide accurate and reliable information to help you navigate the reimbursement process.

    Reimbursement Information for Radiopharmaceuticals: Medicare Coding and Payment for Radiopharmaceuticals Used in Nuclear Medicine Procedures

    Coding and Payment Information

    t-categories-nuclear-imaging-agents-adreview-adreview-medicare-codes-and-payment-rates.jpg

    Under HOPPS, Medicare will continue "packaging" for diagnostic radiopharmaceuticals into the payment for the associated procedure.

    Diagnostic radiopharmaceuticals are separately payable in physician offices and freestanding imaging centers. Payment is based on 95% of the average wholesale price (AWP) or established by local Medicare contractors (carrier priced).

    Physicians performing nuclear medicine procedures using diagnostic radiopharmaceuticals should report the appropriate HCPCS code for the product along with the appropriate CPT® code(s) for the procedure(s). Physicians should make sure the number of units reported is consistent with the quantity of a radiopharmaceutical given to complete the nuclear medicine imaging study.

Professional Resources and Disclosures

Indications and Important Safety Information

JB59281US | Aug 2018